Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease

Inclusion criteria

• Diagnosis of Parkinson's disease (included juvenile parkinsonism) and treated with talipexole (Domin®)
• Patients who present stable symptoms and maintain the doses of talipexole and other concomitant therapy for Parkinson's disease at least last 4 weeks
• Male or female patients aged 20 and over
• In or out-patients
• Patient's severity characterized as Stage 1 - 5 by Modified Hoehn & Yahr scale
• Ability to provide written informed consent in accordance with the Good Clinical Practice (GCP), Good Post-marketing Surveillance Practice (GPMSP) and other relevant laws such as the Pharmaceutical Affairs Law

Exclusion criteria

• History of hypersensitivity of pramipexole
• Psychiatric symptoms such as confusion, hallucination, delusion, agitation, delirium and abnormal behavior
• Subjective symptom derived from orthostatic hypotension
• Hypotension (systolic blood pressure; 100 mmHg or less)
• Complication such as clinically significant cardiac, renal and hepatic diseases
• Patients who drive a car, operate a machine, work on heights or engage in other hazardous activities
• Pregnant, possibly pregnant or female in lactation
• Patients who are participating in other drug studies or who receive other investigational drugs within last 3 months before enrolled this study
• Other than above, those who judged by the investigator or sub-investigator to be inappropriate as for the study